PRID PROGESTERONE RELEASING INTRA-VAGINAL DEVICE
Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
Summary of Product characteristics
(SPC)
18-04-2024
Some documents for this product are not currently available, you can send a request to our customer service and we will notify you as soon as we are able to obtain them.
Send request.
Send request.
Active ingredient:
PROGESTERONE
Available from:
Ceva Animal Health Limited
ATC code:
QG03DA04
Dosage:
1.55 Grams
Pharmaceutical form:
Vaginal Device
Therapeutic group:
Hormone
Therapeutic area:
Bovine
Authorization date:
1987-10-01
Summary of Product characteristics
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
PRID 1.55 g progesterone releasing intra-vaginal device.
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
3 PHARMACEUTICAL FORM
Vaginal delivery system.
A spiral device covered with an inert elastomer containing progesterone.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Cattle (cows and heifers).
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Synchronisation of oestrus in groups of cycling cows and sexually mature heifers. To be used in combination with a
prostaglandin.
Management:
Planned breeding: by synchronising ovarian activity, PRID enables beef cows, dairy cows and heifers to be
inseminated at a predetermined fixed time without the need for oestrus detection, thus reducing the calving index and
the number of cows culled.
4.3 CONTRAINDICATIONS
Do not use in sexually immature heifers.
Do not use in females with abnormal genital tracts e.g. freemartins.
Do not use in animals with genital infections or vaginal discharge.
Do not use in cows and heifers in a poor nutritional state.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Adequate nutrition is required to obtain good fertility results.
Avoid any stress around the treatment period (e.g. sudden dietary changes, vaccination, branding etc.)
Animals should show no discomfort following insertion. In the event of an animal continuing to strain after insertion,
remove the device and serve at the next oestrus.
It is recommended to wait a minimum of 35 days following parturition before starting treatment with this product.
Prostaglandins are contraindicated in pregnancy.
Each spiral device contains:
Active substance
Progesterone
1.55 g
For a full list of excipients, see section 6.1
IRISH MEDICINES BOARD
______________________________________________________________________
Read the complete document
